 BOSTON, May 5, 2021 PRNewswire -- Stealth BioTherapeutics Corp Nasdaq: MITO, a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced the presentation of new data from a post hoc analysis of the Phase 1 ReCLAIM study evaluating elamipretide in patients with non-central geographic atrophy GA and high risk drusen associated with dry age-related macular degeneration AMD. The data, presented at the 2021 Association for Research in Vision and Ophthalmology ARVO Virtual Annual Meeting, showed that for patients with GA treated with elamipretide for 24-weeks, improvements from baseline in low light visual acuity LLVA, which is the primary efficacy endpoint in Stealths fully enrolled Phase 2 ReCLAIM-2 trial, were significantly correlated to baseline assessments of mitochondrial health in the ellipsoid zone EZ. 